Difference between revisions of "Dacarbazine (DTIC)"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - "manufacturer. Instead" to "manufacturer. Instead") |
m |
||
| Line 10: | Line 10: | ||
*[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | *[[Hodgkin lymphoma, nodular lymphocyte-predominant]] | ||
*[[Melanoma]] | *[[Melanoma]] | ||
| − | *[[ | + | *[[Pheochromcytoma]] |
*[[Soft tissue sarcoma]] | *[[Soft tissue sarcoma]] | ||
| Line 39: | Line 39: | ||
[[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | [[Category:Hodgkin lymphoma, nodular lymphocyte-predominant medications]] | ||
[[Category:Melanoma medications]] | [[Category:Melanoma medications]] | ||
| − | [[Category: | + | [[Category:Pheochromocytoma medications]] |
[[Category:Soft tissue sarcoma medications]] | [[Category:Soft tissue sarcoma medications]] | ||
[[Category:Drugs FDA approved in 1975]] | [[Category:Drugs FDA approved in 1975]] | ||
[[Category:WHO Essential Cancer Medicine]] | [[Category:WHO Essential Cancer Medicine]] | ||
Revision as of 01:20, 28 January 2018
General information
Class/mechanism: Alkylator, purine analog, inhibits DNA synthesis; exact mechanism unclear. Converted to the active alkylating metabolite MTIC.[1][2]
Route: IV
Extravasation: irritant
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
- Hodgkin lymphoma
- Hodgkin lymphoma, nodular lymphocyte-predominant
- Melanoma
- Pheochromcytoma
- Soft tissue sarcoma
Patient drug information
- Dacarbazine (DTIC) patient drug information (Chemocare)[3]
- Dacarbazine (DTIC) patient drug information (UpToDate)[4]
History of changes in FDA indication
- 5/27/1975: Initial FDA approval
Also known as
- Generic names: dacarbazin, imidazole carboxamide
- Brand names: Bazipar, Cedcozine, Dacarba, Dacarex, Dacin, Dacmed, Darbazine, Dazine, Decarb, Oncodac, Zydac
References
Categories:
- Drug index
- Intravenous medications
- Irritant chemotherapy
- Alkylating agents
- DNA synthesis inhibitors
- Antimetabolites
- Purine analogues
- Hodgkin lymphoma medications
- Hodgkin lymphoma, nodular lymphocyte-predominant medications
- Melanoma medications
- Pheochromocytoma medications
- Soft tissue sarcoma medications
- Drugs FDA approved in 1975
- WHO Essential Cancer Medicine